Abcentra's pharmaceutical products are investigational and not FDA approved
© 2022 Abcentra™ . All Rights Reserved.
Chris Farina is the Vice President of Operations and Chief of Staff for Abcentra. He has been with the team since 2013, and has held the positions Senior Project Manager and Director of R&D Program Management before his current role. Mr. Farina is a co-inventor on several patents related uses of orticumab to treat human diseases. He also co-authored a peer-reviewed article published in Scientific Reports on the effect of anti-oxLDL antibodies in mice.
Mr. Farina previously worked for Cedars-Sinai Medical Center’s Comprehensive Transplant Program as a perfusionist and transplant technician.
Mr. Farina holds Bachelor of Arts (B.A.) in Communication and a Master of Science (M.S.) Management of Drug Development from the University of Southern California. He also holds a Regulatory Affairs Certification (RAC) from The Regulatory Affairs Professional Society.
Dunér, P., Mattisson, I.Y., Fogelstrand, P. et al. Antibodies against apoB100 peptide 210 inhibit atherosclerosis in apoE-/- mice. Sci Rep 11, 9022 (2021). https://doi.org/10.1038/s41598-021-88430-1